Switch theme
Sign up to access all valuation multiples
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington’s Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
1995
183
LTM Revenue $61.1M
LTM EBITDA -$65.9M
$157M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sangamo Therapeutics has a last 12-month revenue of $61.1M and a last 12-month EBITDA of -$65.9M.
In the most recent fiscal year, Sangamo Therapeutics achieved revenue of $57.8M and an EBITDA of -$89.1M.
Sangamo Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sangamo Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $176M | $57.8M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$96.8M | -$89.1M | XXX | XXX | XXX |
| EBITDA Margin | -55% | -154% | XXX | XXX | XXX |
| Net Profit | -$192M | -$258M | XXX | XXX | XXX |
| Net Margin | -109% | -446% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Sangamo Therapeutics's stock price is $1.
Sangamo Therapeutics has current market cap of $169M, and EV of $157M.
See Sangamo Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $157M | $169M | XXX | XXX | XXX | XXX | $-0.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Sangamo Therapeutics has market cap of $169M and EV of $157M.
Sangamo Therapeutics's trades at 2.6x LTM EV/Revenue multiple, and -2.4x LTM EBITDA.
Analysts estimate Sangamo Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Sangamo Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $157M | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | -1.8x | XXX | XXX | XXX |
| P/E | -1.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSangamo Therapeutics's NTM/LTM revenue growth is 6%
Sangamo Therapeutics's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Sangamo Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Sangamo Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Sangamo Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -67% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -154% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -8% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -148% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 77% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 193% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 270% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sangamo Therapeutics acquired XXX companies to date.
Last acquisition by Sangamo Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Sangamo Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Sangamo Therapeutics founded? | Sangamo Therapeutics was founded in 1995. |
| Where is Sangamo Therapeutics headquartered? | Sangamo Therapeutics is headquartered in United States of America. |
| How many employees does Sangamo Therapeutics have? | As of today, Sangamo Therapeutics has 183 employees. |
| Who is the CEO of Sangamo Therapeutics? | Sangamo Therapeutics's CEO is Dr. Alexander Donald Macrae, M.B.,PhD. |
| Is Sangamo Therapeutics publicy listed? | Yes, Sangamo Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Sangamo Therapeutics? | Sangamo Therapeutics trades under SGMO ticker. |
| When did Sangamo Therapeutics go public? | Sangamo Therapeutics went public in 2000. |
| Who are competitors of Sangamo Therapeutics? | Similar companies to Sangamo Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Sangamo Therapeutics? | Sangamo Therapeutics's current market cap is $169M |
| What is the current revenue of Sangamo Therapeutics? | Sangamo Therapeutics's last 12-month revenue is $61.1M. |
| What is the current EBITDA of Sangamo Therapeutics? | Sangamo Therapeutics's last 12-month EBITDA is -$65.9M. |
| What is the current EV/Revenue multiple of Sangamo Therapeutics? | Current revenue multiple of Sangamo Therapeutics is 2.6x. |
| What is the current EV/EBITDA multiple of Sangamo Therapeutics? | Current EBITDA multiple of Sangamo Therapeutics is -2.4x. |
| What is the current revenue growth of Sangamo Therapeutics? | Sangamo Therapeutics revenue growth between 2023 and 2024 was -67%. |
| Is Sangamo Therapeutics profitable? | Yes, Sangamo Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
